Oct 02, 2024 9:10am EDT TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
Aug 21, 2024 9:00am EDT TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
Jul 24, 2024 9:05am EDT TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
Jul 22, 2024 9:00am EDT MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
Jun 17, 2024 9:00am EDT MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
Mar 05, 2024 9:15am EST MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Feb 13, 2024 11:45am EST MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Dec 06, 2023 9:15am EST MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
Oct 04, 2023 7:30am EDT MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
